FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a prominent player in the biopharmaceutical industry, is headquartered in Grand Island, New York, with significant operations across the United States and Europe. Founded in 2012, the company has rapidly established itself as a leader in biomanufacturing, specialising in the development and production of biologics, including monoclonal antibodies and recombinant proteins. With a commitment to innovation, FUJIFILM Diosynth offers unique services such as cell line development, process development, and large-scale manufacturing, utilising cutting-edge technologies to ensure high-quality outputs. The company has achieved notable milestones, including partnerships with major pharmaceutical firms, solidifying its market position as a trusted contract development and manufacturing organisation (CDMO). Through its dedication to excellence, FUJIFILM Diosynth continues to advance the biopharmaceutical landscape, supporting the delivery of life-saving therapies worldwide.
DitchCarbon Score
How does FUJIFILM Diosynth Biotechnologies U.S.A., Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.'s score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.'s reported carbon emissions
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., headquartered in Great Britain, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions, are not provided. In the absence of emissions data, it is important to note that the company has not outlined any specific reduction targets or climate commitments. This lack of publicly available information may suggest that they are still in the process of developing their climate strategy or have not yet formalised their commitments to carbon reduction. As the biotechnology industry increasingly prioritises sustainability, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. may be expected to align with industry standards and practices in addressing climate change and reducing carbon emissions in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
